FIELD: medicine.
SUBSTANCE: invention refers to experimental medicine, namely to experimental nephrology and can be used for simulating experimental amyloidosis in animals. That is ensured by subcutaneous introduction of native ovalbumin to old rats every second day at 0.025 ml/g of body weight within 60 days of the experiment.
EFFECT: enhanced simulation of experimental amyloidosis in animals.
1 ex, 2 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF MODELLING EXPERIMENTAL AMYLOIDOSIS IN RATS | 2009 |
|
RU2410761C1 |
| METHOD OF PREVENTING SYSTEMIC AMYLOIDOSIS AND ITS NEPHROPATIC FORM IN EXPERIMENTAL ANIMALS | 2009 |
|
RU2410764C1 |
| METHOD FOR SIMULATING GENERALISED AMYLOIDOSIS IN ANIMALS | 2013 |
|
RU2536556C2 |
| METHOD OF EXPERIMENTAL AMYLOIDOSIS MODELLING IN ANIMALS | 2007 |
|
RU2347279C1 |
| METHOD FOR PREVENTION OF SYSTEMIC AMYLOIDOSIS AND ITS NEPHROPATHIC CONDITION IN EXPERIMENTAL ANIMALS | 2008 |
|
RU2386415C1 |
| METHOD OF TREATMENT AN EXPERIMENTAL AMYLOID CARDIOPATHY IN RATS | 2017 |
|
RU2657844C1 |
| METHOD FOR PREVENTION OF SYSTEMIC AMYLOIDOSIS AND ITS NEPHROPATHIC FORM IN EXPERIMENTAL ANIMALS | 2011 |
|
RU2473134C2 |
| METHOD FOR SIMULATION OF EXPERIMENTAL AMYLOIDOSIS IN ANIMALS | 2010 |
|
RU2446482C1 |
| METHOD FOR SIMULATING EXPERIMENTAL AMYLOID CARDIOPATHY IN RATS | 2013 |
|
RU2556571C1 |
| METHOD FOR MODELING EXPERIMENTAL AMYLOIDOSIS IN ANIMALS | 2004 |
|
RU2269825C1 |
